News and Announcements
Web 3.0: Real Digital Ownership & Opportunities
- Published November 03, 2022 7:13AM UTC
- Publisher Maan Perez
- Categories Venture Investor Interviews
One of the central tenets of Web3 is digital ownership where users will have the power to decide if they want to share their data, choose which entities to share it with, and define the terms under which the data can be shared.
During Venture and Capital 2022, Heath Behncke of Holon explained the difference between Web3 and Web2 in terms of enabling data custody.
As co-founder of Holon, Heath is a global equities and digital asset portfolio manager investing in businesses and networks taking advantage of global digital innovation, as well as being an active participant in Web 3.0 infrastructure.
Looking for new investment opportunities? Click here to browse hundreds of companies, connect with their CEO and create your personalised deal flow.
Your AI Driven matchmaking platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Venture Investor Interviews
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
